Not exact matches
Study of the safety,
pharmacodynamics and efficancy of KRN23 in children from 1 to 4 years old
with X-linked Hypophosphatemia (XLH).
In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials,
with a specific emphasis on
pharmacodynamic biomarker identification.
To create a longer - lasting preventive therapy for severe hemophilia A-associated bleeding, a group of Japanese researchers launched a first - in - human Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of ACE910, a bispecific antibody that mimics FVIII and works
with other clotting factors to make the blood clot properly.
A Phase 1 / 2a Study to Assess the Safety, Pharmacokinetics, and
Pharmacodynamics of PLX8394 in Patients
with Advanced, Unresectable Solid Tumors
A Phase 1b / 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Efficacy of AMG 232 Combined
with Trametinib and Dabrafenib or Trametinib in Adult Subjects
with Metastatic Cutaneous Melanoma
A Phase 1b / 2 Open - Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and
Pharmacodynamics of Avelumab (MSB0010718C) in Combination
with Other Cancer Immunotherapies in Patients
with Advanced Malignancies
The second study, FIREFISH, is aimed to assess safety, tolerability, pharmacokinetics,
pharmacodynamics, and efficacy in infants
with Type I SMA.
An Open - Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and
Pharmacodynamics of H3B - 6527 in Subjects
with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Well - characterized drugs may come
with detailed knowledge of their
pharmacodynamics, pharmacokinetics and side effects as well as
with established regimens for clinical applications.
There are no any drugs
with the same action mechanism, but Russian regulators wanted to know, for example,
pharmacodynamics of the VEGF expressed from the plasmid.
Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor
pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases
with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters
These results serve as a rationale for ONC201 single - agent trials in relapsed / refractory acute leukemia, non-Hodgkin's lymphoma, MM and combination trial
with dexamethasone in MM, provide
pharmacodynamic biomarkers and identify further synergistic combinatorial regimens that can be explored in the clinic.
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and
pharmacodynamic analysis of hydroxychloroquine in combination
with the HDAC inhibitor vorinostat in patients
with advanced solid tumors.
The clinical pharmacist is a licensed professional
with knowledge and proficiency in pharmacy practice including pharmaceutics, pharmacokinetics,
pharmacodynamics and pharmaco - therapeutics.